Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.23 and traded as low as $0.85. Spero Therapeutics shares last traded at $0.91, with a volume of 371,185 shares.

Wall Street Analyst Weigh In

SPRO has been the subject of a number of research reports. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research note on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a research note on Monday, December 2nd.

Spero Therapeutics Price Performance

The company has a market cap of $47.65 million, a P/E ratio of 12.49 and a beta of 0.63. The stock has a fifty day moving average price of $1.07 and a two-hundred day moving average price of $1.23.

Institutional Trading of Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC boosted its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 975,952 shares of the company’s stock after purchasing an additional 121,492 shares during the period. Renaissance Technologies LLC owned about 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.